Bone Morphogenetic Proteins
"Bone Morphogenetic Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bone-growth regulatory factors that are members of the transforming growth factor-beta superfamily of proteins. They are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins.
| Descriptor ID |
D019485
|
| MeSH Number(s) |
D12.644.276.954.200 D12.776.467.942.200 D23.529.942.200
|
| Concept/Terms |
Bone Morphogenetic Proteins- Bone Morphogenetic Proteins
- Morphogenetic Proteins, Bone
- Bone Morphogenetic Protein
- Morphogenetic Protein, Bone
|
Below are MeSH descriptors whose meaning is more general than "Bone Morphogenetic Proteins".
Below are MeSH descriptors whose meaning is more specific than "Bone Morphogenetic Proteins".
This graph shows the total number of publications written about "Bone Morphogenetic Proteins" by people in this website by year, and whether "Bone Morphogenetic Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 4 | 0 | 4 |
| 2003 | 7 | 1 | 8 |
| 2004 | 3 | 0 | 3 |
| 2005 | 11 | 2 | 13 |
| 2006 | 13 | 2 | 15 |
| 2007 | 10 | 0 | 10 |
| 2008 | 5 | 4 | 9 |
| 2009 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bone Morphogenetic Proteins" by people in Profiles.
-
Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. JCI Insight. 2018 06 07; 3(11).
-
Neuroforaminal Bone Growth Following Minimally Invasive Transforaminal Lumbar Interbody Fusion With BMP: A Computed Tomographic Analysis. Clin Spine Surg. 2017 Jul; 30(6):E754-E758.
-
Acute Phosphate Restriction Impairs Bone Formation and Increases Marrow Adipose Tissue in Growing Mice. J Bone Miner Res. 2016 12; 31(12):2204-2214.
-
Bone Morphogenetic Proteins in Lumbar Arthrodesis: What Is All the Debate About? Commentary on an article by Daniel C. Beachler, PhD, MHS, et al.: "Bone Morphogenetic Protein Use and Cancer Risk Among Patients Undergoing Lumbar Arthrodesis: A Case-Cohort Study Using the SEER-Medicare Database". J Bone Joint Surg Am. 2016 07 06; 98(13):e57.
-
Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression. BMC Musculoskelet Disord. 2015 Nov 26; 16:368.
-
Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis. J Bone Joint Surg Am. 2015 Jan 21; 97(2):133-40.
-
Fusion in degenerative spondylolisthesis: comparison of osteoconductive and osteoinductive bone graft substitutes. Eur Spine J. 2015 May; 24(5):1066-73.
-
Epidemiological trends in the utilization of bone morphogenetic protein in spinal fusions from 2002 to 2011. Spine (Phila Pa 1976). 2014 Mar 15; 39(6):491-6.
-
Current trends in demographics, practice, and in-hospital outcomes in cervical spine surgery: a national database analysis between 2002 and 2011. Spine (Phila Pa 1976). 2014 Mar 15; 39(6):476-81.
-
Complications of spinal fusion with utilization of bone morphogenetic protein: a systematic review of the literature. Spine (Phila Pa 1976). 2014 Jan 01; 39(1):91-101.